Neurodegenerative Disease Management – meeting the challenge of neurodegenerative diseases

NewsGuard 100/100 Score

Future Medicine Ltd has today announced the launch of Neurodegenerative Disease Management – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world.

Neurodegenerative Disease Management is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.

Neurodegenerative Disease Management presents findings, analysis and commentary in the ongoing battle with a broad range of debilitating neurodegenerative illnesses. The journal provides guidance to the multidisciplinary disease management community regarding the most effective treatment strategies and the implications of cutting-edge research as it emerges.

Neurodegenerative Disease Management provides concise and clear coverage of topics at the forefront of research, which impact the understanding, treatment and management of major neurodegenerative diseases. Articles take the form of reviews, analysis and original articles which cover a broad range of topics including all neurodegenerative diseases; from Alzheimers to multiple sclerosis, disease mechanisms, epidemiology, genetic and environmental influences on disease pathogenesis, pharmacoeconomics, outcomes research, quality of life and much more. Articles are subject to peer-review by three independent referees on a double-blind basis. Authors publishing in the journal are asked to disclose any professional or financial interest that may be perceived as causing a conflict of interest in the context of the article.

Anthony HV Schapira of the UCL Institute of Neurology, UK and Bruno Dubois of the hôpital La Salpêtrière, France are in charge of the editorial direction of Neurodegenerative Disease Management acting as Associate Editors, they are supported by a team of international experts making up the editorial advisory board. Anthony HV Schapira commented “Our journal fills an important gap in the current market of knowledge. Neurodegenerative Disease Management seeks to provide a comprehensive and up-to-date information service for those with an interest in neurodegenerative diseases in the broadest sense. The journal intends to take full advantage of the emerging multimedia approach to medical education in order to provide data and reflections in a timely manner

Elisa Manzotti, Editorial Director at Future Medicine, said, “The input of all involved in Neurodegenerative Disease Management has been invaluable to ensure we have a robust launch in this exciting arena of research and practice.

Manzotti went on to say, Neurodegenerative Disease Management will comprise topical, concise articles bringing together all disciplines of the treatment of neurodegenerative disease. All submitted articles will be subjected to rigorous and constructive peer review by at least three independent referees.

Selected content from the launch issue can be viewed at www.futuremedicine.com/loi/nmt. If you are interested in receiving a free 30-day online trial to evaluate the journals content please contact [email protected], quoting NMTPR11.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Dietary vitamin A shows promise in Alzheimer's disease intervention, study finds